clinical trial · NCT05367960
An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome
Tetra Discovery Partners·phase3·active not recruiting·n = 314
Fragile X SyndromeZatolmilast/ BPN14770
brief summary
This is a 4-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301 (in adult males) and Study BPN14770-CNS-204 (in adolescent males).
started
Nov 1, 2022
primary completion
Sep 30, 2027
completion
Dec 31, 2027
last updated
Oct 3, 2025
detailed description
This is a 4-year open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301 (in adult males) and Study BPN14770-CNS-204 (in adolescent males). The primary objective of this OLE is to assess the long-term safety and tolerability of BPN14770 in these subjects with fragile X syndrome (FXS) who were treated in one of those parent clinical trials.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol